>
MabVax Therapeutics Holdings Inc logo

MBVXQ - MabVax Therapeutics Holdings Inc Share Price

$0.023 0.0  0.0%

Last Trade - 19/03/20

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £3.43m
Position in Universe th / 7170
Bullish
Bearish
Unlock MBVXQ Revenue
Momentum
Relative Strength (%)
1m -24.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 2018E 2019E CAGR / Avg
0.000 0.37 0.31 1.27 0.15 0.000 0.001 0.001
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2018, MabvaxTherapeutics Holdings Inc revenues increased from $0K to$4.7M. Net loss applicable to common stockholders decreased68% to $7.3M. Revenues reflect an increase in demand forthe Company's products and services due to favorable marketconditions. Lower net loss reflects Research anddevelopment decrease of 53% to $2.9M (expense), General andadministrative decrease of 15% to $6.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

MBVXQ Revenue Unlock MBVXQ Revenue

Net Income

MBVXQ Net Income Unlock MBVXQ Revenue

Normalised EPS

MBVXQ Normalised EPS Unlock MBVXQ Revenue

PE Ratio Range

MBVXQ PE Ratio Range Unlock MBVXQ Revenue

Dividend Yield Range

MBVXQ Dividend Yield Range Unlock MBVXQ Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
MBVXQ EPS Forecasts Unlock MBVXQ Revenue
Profile Summary

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer and pancreatitis. The Company discovered a pipeline of human monoclonal antibody product candidates based on the immune responses generated by patients. The Company's product pipeline includes ImmunoPET Imaging (MVT-2163) and Radioimmunotherapy (MVT-1075). MVT-2163 is an imaging agent for pancreatic cancer. MVT-1075 is a radioimmunotherapy for pancreatic cancer.

Directors
Last Annual December 31st, 2017
Last Interim September 30th, 2018
Incorporated October 20, 1988
Public Since August 11, 2000
No. of Shareholders: n/a
No. of Employees: 22
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OTC Markets Group
Shares in Issue 9,429,582
Free Float (0.0%)
Eligible for
× ISAs
SIPPs
MBVXQ Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for MBVXQ
Upcoming Events for MBVXQ
Frequently Asked Questions for MabVax Therapeutics Holdings Inc
What is the MabVax Therapeutics Holdings Inc share price?

As of 19/03/20, shares in MabVax Therapeutics Holdings Inc are trading at $0.023, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the MabVax Therapeutics Holdings Inc share price performed this year?

Shares in MabVax Therapeutics Holdings Inc are currently trading at $0.023 and the price has moved by -92.37% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the MabVax Therapeutics Holdings Inc price has moved by -94.26% over the past year.

What are the analyst and broker recommendations for MabVax Therapeutics Holdings Inc?

There are no analysts currently covering MabVax Therapeutics Holdings Inc.

When will MabVax Therapeutics Holdings Inc next release its financial results?

MabVax Therapeutics Holdings Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2019-09-30
What is the MabVax Therapeutics Holdings Inc dividend yield?

MabVax Therapeutics Holdings Inc does not currently pay a dividend.

Does MabVax Therapeutics Holdings Inc pay a dividend?

MabVax Therapeutics Holdings Inc does not currently pay a dividend.

When does MabVax Therapeutics Holdings Inc next pay dividends?

MabVax Therapeutics Holdings Inc does not currently pay a dividend.

How do I buy MabVax Therapeutics Holdings Inc shares?

To buy shares in MabVax Therapeutics Holdings Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of MabVax Therapeutics Holdings Inc?

Shares in MabVax Therapeutics Holdings Inc are currently trading at $0.023, giving the company a market capitalisation of £n/a.

Where are MabVax Therapeutics Holdings Inc shares listed? Where are MabVax Therapeutics Holdings Inc shares listed?

Here are the trading details for MabVax Therapeutics Holdings Inc:

Country of listing: United States
Exchange: OTC
Ticker Symbol: MBVXQ
What kind of share is MabVax Therapeutics Holdings Inc?

We were not able to load our ranking data for MabVax Therapeutics Holdings Inc

Is there a MabVax Therapeutics Holdings Inc share price forecast 2021?

We were not able to load any forecast data for MabVax Therapeutics Holdings Inc.

How can I tell whether the MabVax Therapeutics Holdings Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MabVax Therapeutics Holdings Inc. Over the past six months, the relative strength of its shares against the market has been 12.77%. At the current price of $0.023, shares in MabVax Therapeutics Holdings Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the MabVax Therapeutics Holdings Inc PE Ratio?

We were not able to find PE ratio data for MabVax Therapeutics Holdings Inc.

Who are the key directors of MabVax Therapeutics Holdings Inc?

MabVax Therapeutics Holdings Inc's management team is headed by:

J. David Hansen - CHM
Philip Livingston - CSO
Kenneth Cohen - IND
Paul Maier - IND
Gregory Hanson - CFO
Thomas Varvaro - IND
Paul Maffuid - VOP
Jeffrey Eisenberg - DRC
Paul Resnick - VPR
Who are the major shareholders of MabVax Therapeutics Holdings Inc?

Here are the top five shareholders of MabVax Therapeutics Holdings Inc based on the size of their shareholding:

Similar to MBVXQ
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.